CanAdelaar

What CanAdelaar does

CanAdelaar B.V. is a Dutch independent cannabis cultivator and one of 10 officially licensed growers authorized to produce and supply recreational cannabis within the Netherlands' Wietexperiment, a government-run pilot program that launched in 2023 and represents Europe's largest regulated adult-use cannabis market. Founded in December 2018 and headquartered in Amsterdam with its primary production facility in Hellevoetsluis (southern Netherlands), the company controls the full supply chain — from genetic development and greenhouse cultivation under natural sunlight through product development to direct distribution to licensed coffeeshops. Its product portfolio spans more than 20 proprietary cannabis genetics sold under the COG (Canadelaar Original Grow) brand in three formats: dried flower, pre-rolls, and hash.

The company operates an ultra-modern greenhouse facility staffed by 125+ personnel including expert growers, biochemists, and quality controllers, supported by on-site research laboratories and an advanced air purification system (more than €3 million invested, with 200+ carbon filters and 70+ ASPRA roof units). Operational technology includes a decrypted Track & Trace QR system providing full product provenance from harvest through retail. The business model is B2B-direct: CanAdelaar supplies regulated cannabis products exclusively to licensed coffeeshops participating in the Wietexperiment, currently reaching 70+ retail outlets across 10 municipalities. Pricing is not publicly disclosed; transactions are conducted under government oversight from the Dutch Ministry of Justice and Security. In December 2025, CanAdelaar signed a definitive agreement to be acquired by Cronos Group (Nasdaq: CRON) for approximately €57.5 million (~$67 million) upfront plus contingent consideration tied to normalized EBITDA in 2026 and 2027, with the transaction closing in February 2026 at a valuation of roughly 1.4x LTM revenue and 2.4x LTM EBITDA. CanAdelaar continues to operate from the Netherlands under the Cronos umbrella, preserving local production and employment as required by Dutch regulations.

Name

CanAdelaar

Legal name

CanAdelaar B.V.

Website

https://canadelaar.com

Company type

Private

Founded year

2018

Operating status

Acquired

Headcount range

101–250 employees

Short description

CanAdelaar B.V. is a Dutch cannabis cultivator and one of 10 licensed growers supplying regulated recreational cannabis to 70+ coffeeshops across 10 municipalities under the Netherlands' Wietexperiment. Now a Cronos Group subsidiary following a 2026 acquisition.

Ownership category

akta.pro rank

Product category

Regulated Cannabis Cultivation & Distribution

NAICS

Coffee and Tea Manufacturing (311920), Greenhouse, Nursery, and Floriculture Production (1114)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Coffee & Cacao Plantations (Coffee, Cocoa) (AFAGACAI)

Keywords

• Regulated cannabis cultivation
• Cannabis product manufacturing
• Cannabis wholesale distribution
• Adult-use cannabis supply
• Cannabis genetic development

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Cannabis Product Sales to Coffeeshops: B2B sales of cannabis products (flower, pre-rolls, hash) to licensed coffeeshops participating in the Dutch Wietexperiment. Products sold under the COG (Canadelaar Original Grow) brand across 70+ coffeeshops in 10 municipalities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

CanAdelaar cultivates, processes, and distributes regulated recreational cannabis products (flowers, pre-rolls, and hash) under its COG (Canadelaar Original Grow) brand, selling wholesale to licensed Dutch coffeeshops participating in the Netherlands' Wietexperiment. The company controls the entire supply chain from proprietary genetic development (20+ strains) through sungrown greenhouse cultivation to retail distribution across 70+ coffeeshops in 10 municipalities.

Product overview

CanAdelaar is a Dutch independent cannabis cultivator and one of the official growers within the Netherlands' Wietexperiment (weed experiment) regulatory framework. Founded in 2018 and based in Hellevoetsluis, the company operates the full supply chain from genetics and cultivation to product development and distribution. Their consumer-facing brand is COG (Canadelaar Original Grow), under which they offer over 20 unique cannabis genetics in multiple forms: flowers, pre-rolls, and hash. Products are distributed through a network of 70+ regulated coffeeshops across 10 Dutch municipalities participating in the experiment. The company was acquired by Cronos Group in 2025 for approximately €57.5 million, positioning CanAdelaar as Europe's largest adult-use cannabis company within the regulated Dutch market.

Differentiator

Problem solved

Functional benefit

Products and services

• COG (Canadelaar Original Grow) The primary consumer-facing brand under which CanAdelaar sells its regulated cannabis products to Dutch coffeeshops participating in the Wietexperiment.
• Cannabis Flowers Dried cannabis flower products cultivated under natural sunlight at CanAdelaar's Hellevoetsluis greenhouse facility, sold wholesale to licensed coffeeshops participating in the Wietexperiment for retail sale to adult consumers.
• Pre-rolls Pre-rolled cannabis products made from CanAdelaar's proprietary sungrown genetics, offering ready-to-use cannabis products to licensed Dutch coffeeshops within the regulated market.
• Hash Cannabis hash derived from CanAdelaar's cultivated sungrown genetics, sold as part of its diverse product portfolio to licensed Dutch coffeeshops participating in the Wietexperiment.
• Cannabis Genetics (Genetic Catalog) Over 20 unique cannabis genetics developed in-house, including Dutch and international varieties, offered as sungrown and natural products cultivated in the Netherlands. Available in flower, pre-roll, and hash forms.

Quantifiable outcome

• First legal sale of THC products for recreational use in Europe achieved in December 2023
• +1 more outcomes

Named customers5 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Cronos GroupcoreStrategic or Co-development Partner · 9 December 2025Cronos Group, a major innovative player in the global legal cannabis industry, acquired CanAdelaar for approximately €57.5 million upfront (US$67 million) plus contingent consideration based on 0.5x normalized EBITDA in 2026 and 2027. The acquisition gives Cronos the leading market share in Europe's largest adult-use cannabis market through the Netherlands' Wietexperiment. Cronos brings global expertise, R&D capabilities, advanced genetics, and resources to support CanAdelaar's continued operations and quality standards. CanAdelaar products will continue to be cultivated in the Netherlands, preserving local production and employment.

Scale indicators7 records

Expansion highlights4 records

Direct peers

• Bedrocan: Bedrocan is a Dutch licensed medicinal cannabis cultivator and one of the established producers in the Netherlands. It is directly comparable to CanAdelaar in regulated Dutch cannabis cultivation, though its primary focus is medical rather than adult-use.
• Demecan: Demecan is a German licensed cannabis cultivator producing under the German medical cannabis framework. It is comparable as a regulated European cannabis producer, but operates in a different national framework (Germany vs. Netherlands) and primarily in the medical channel.

Broad incumbents

• Tilray Brands: Tilray is a global cannabis major with cultivation operations across multiple jurisdictions. It is comparable to CanAdelaar's parent (Cronos) as a broad incumbent cannabis operator with global reach, though Tilray's portfolio is far larger and more diversified than CanAdelaar's single-country focus.
• Aurora Cannabis: Aurora is a global cannabis producer with EU-GMP-certified cultivation capacity. Comparable to CanAdelaar as a multi-jurisdiction licensed cultivator serving regulated medical and adult-use markets, though Aurora operates at significantly larger scale across multiple countries.
• Canopy Growth: Canopy Growth is a major global cannabis operator with European operations and broad product portfolios. Comparable as a broad-incumbent cannabis producer with regulated-market exposure, though Canopy's scale, geographic reach, and product diversification exceed CanAdelaar's.
• Cronos Group: Cronos Group is the parent of CanAdelaar and a Nasdaq-listed global cannabis company. Comparable as a broad-incumbent operator in regulated cannabis, with CanAdelaar now functioning as Cronos's primary European cultivation and distribution platform.
• Organigram Holdings: Organigram is a Canadian licensed cannabis producer with domestic and international operations. Comparable as a broad-incumbent cannabis cultivator with regulated-market exposure, though Organigram is primarily Canada-focused and does not currently have a Dutch cultivation presence.

Emerging players

• Cantourage: Cantourage is a German cannabis company focused on distribution of medical cannabis from multiple international producers into the German market. Comparable as a European-focused emerging cannabis player, though Cantourage is primarily a distributor rather than a cultivator like CanAdelaar.
• Sanity Group: Sanity Group is a Berlin-based European cannabis company operating across cultivation, processing, and medical distribution in Germany. Comparable as an emerging European cannabis operator with regulated-market exposure, though its primary jurisdiction is Germany rather than the Netherlands.

Others

• Cansativa: Cansativa operates one of the largest German cannabis distribution platforms, working with multiple licensed producers to supply German pharmacies. Comparable as an adjacent ecosystem participant in the European regulated cannabis supply chain, though Cansativa is a distributor rather than a producer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/canadelaar

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CanAdelaar